

SORAFENIB IN HEPATOCARCINOMA: RESULTS IN A REAL WORLD SETTING

4CPS-302

*J Hernández Parada, M Carrasco Gomariz, A Perea Pérez, MJ Cárdenas Aranzana, JR del Prado Llergo
Hospital Universitario Reina Sofía, Pharmacy Department, Córdoba, Spain*

Background

Sorafenib is an option for patients with advanced unresectable hepatocarcinoma (HCC) who are unsuitable for locoregional therapy and whose liver function is adequate to tolerate therapy (Child Pugh A or B).

Purpose

To evaluate the effectiveness and safety of sorafenib in adults with metastatic HCC in our clinical practice

Material and methods

Observational, retrospective and descriptive study.

Records (by electronic clinical history):

- Age
- Sex
- Barcelona Clinic Liver Cancer (BCLC) staging
- Adverse events (AEs)
- Need for dose reduction or discontinuation
- Time to progression or death

TIME LAPSE



None of the patients had received previous systemic therapy.

The analysis were performed using R Studio version 4.0.3.

Results

47 patients with metastatic HCC were treated with sorafenib.


Age (years): 63 (46-81).

Sex (no. (%)):

Male 42 (91.5%)


Female 5 (8.5%)

BCLC stage



The **median of overall survival (mOS) was 17.9 months**, range 0.5 to 24.0; 95% confidence interval [CI] (15.5 to not reached).

The main AEs



The rate of discontinuation due to AEs was 29.8%.
Thirty-four patients (72.3%) required dose reduction.

The most common reasons for treatment discontinuation:

- AEs (14 patients)
- Progression (22 patients).

Conclusion

In our setting mOS was superior than reported in the pivotal clinical trial even though the baseline characteristics were similar.

Some of the AEs were more frequently like fatigue, hand-foot skin reaction, hypertension and anorexia although the rate of discontinuation due to AEs was lower than reported in SHARP trial.

References and/or acknowledgements

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. PMID: 18650514.

No conflict of interest.